Precision Medicine Market Size, Share, Trends | Opportunities, Demands and Growth Revenue by 2026 | Brandessence Market Research Report

The MarketWatch News Department was not involved in the creation of this content.

Dec 03, 2020 (Heraldkeepers) —
The Precision Medicine Market delivers a succinct analysis on industry size, regional growth and revenue forecasts for the upcoming years. The report further sheds light on significant challenges and latest growth strategies adopted by manufacturers who are a part of the competitive spectrum of this business domain.

Precision Medicine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025. The growth in the precision medicine market is propelled by an increasing demand for personalized treatment; technological innovation and advancement , as well as growth of personal healthcare devices are major key factor which drives the Global Precision Medicine Market.

Get Sample Copy of This Premium Report https://brandessenceresearch.com/requestSample/PostId/55

**The sample pages of this report is immediately accessible on-demand.**

Top Precision Medicine companies:

key strategies followed by the top players operating in the precision medicine market are,

  • Abbott Laboratories
  • GE Healthcare
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Pfizer
  • Laboratories Corporation of America Holdings
  • Danaher Corporation
  • Biocrates Life Sciences AG
  • Nanostring Technologies
  • Intomics
  • Ferrer Incode
  • Eagle Genomics Ltd

Scope of Market Reports –

Precision medicine is often called as Personalized Medicine. It is used to describe how genetic information about a person’s disease is being used to diagnose or treat their disease. Precision Medicine refers to the modification of medical treatment to the individual characteristics of each patient. It does not exactly mean the manufacturing of drugs or medical devices that are unique to a patient, but the ability to categorize individuals into sub-populations that diverge in their susceptibility to a particular disease. Preventive or therapeutic interventions can then be focused on those who will benefit, sparing cost and side effects for those who will not. The main aim of government regulations is to make Precision Medicines more accepted and it is focused towards genetic diseases related to oncology, skin, respiratory, central nervous system, cardiovascular, and infectious diseases.

The key objective of Cancergenomics is to improve personalized medicine through the DNA sequencing and analysis of patient tumors cells to find out new genetic mutation associated with specific cancers.

Genetic information has helped to increase the development and use of the newest cancer treatments like Chemotherapy, Radiation Therapy, Targeted Therapy and Precision Medicines. For example, the drug Imatinib was modified to inhibit an altered enzyme produced by a fused version of two genes found in chronic myelogenousleukemia. Another example is the breast cancer drug Trastuzumab which works only for women whose tumors have a particular genetic profile calledHuman Epidermal Growth Factor Receptor 2(HER-2 positive). It is also found that lung cancer patients whose tumors are positive forEstimated Glomerular Filtration Rate (EGFR)mutations will respond to the drugs Gefitinib and Erlotinib which target this mutation. Conversely, colon cancer patients whose tumors have a mutation in a gene called KRAS (K-RAS) derive less benefit from the drugs Cetuximab and Panitumumab. The genomic information made by The Cancer Genome Atlas (TCGA) will boostthe research to develop similar treatment strategies for

Read more

DermTech Presents Updates in Precision Medicine at 2020 Dermatology Drug Development Summit

DermTech, Inc. (NASDAQ:DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the presentation of a precision medicine focused session at the fourth annual Dermatology Drug Development Summit. Held virtually this year, the Dermatology Drug Development Summit is the only industry-focused meeting dedicated to innovating, accelerating, and sharing pharmaceutical best practice on the development and bringing to market of new dermatological drugs, in the treatment of high unmet need. 

The session, titled, “Stickering it to Skin Disease: The Drive for Precision and Personalized Dermatology,” presented by Michael D. Howell, PhD, Chief Scientific Officer of DermTech, explored the current approaches to precision medicine in dermatology and the integration of precision medicine and biomarker approaches in clinical trials. Howell reviewed DermTech’s proprietary Smart Sticker platform and its use in early detection of skin cancers including cutaneous melanoma. Howell also discussed how non-invasive skin sampling can enhance precision medicine by detecting genomic and proteomic changes in the skin without the need for a skin biopsy. Finally, Howell discussed how the expanded use of DermTech’s breakthrough tool can guide personalized approaches to disease diagnosis and intervention.

The presentation is available for viewing here.

“The Dermatology Drug Development Summit brings together leaders in academia, government, and industry with a goal of driving innovative medicine in dermatology. The DermTech Smart Sticker is an innovative platform that non-invasively assesses genomic and proteomic changes in the skin before those changes can be visually detected. With more than 3,000 potentially identifiable dermatological diseases and an ever increasing armamentarium of therapies, the Smart Sticker technology enables innovative approaches to precision and personalized dermatology,” commented Howell.

About DermTech:

DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform the practice of dermatology through more accurate diagnosis and treatment, and the elimination of unnecessary surgery, leading to improved patient care and lower costs. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.

Forward-looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the Smart Sticker platform, and the market opportunity therefor. These forward-looking statements involve

Read more

QurAlis to Present Data on Two Precision Medicine Programs (Kv7 and TBK1) at MNDA 31st International Symposium on ALS/MND – Press Release

CAMBRIDGE, Mass.–(Business Wire)–QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced that the company will present two posters featuring data from two of the company’s preclinical precision medicine ALS programs at the Motor Neuron Disease Association (MNDA) 31st International Symposium on ALS/MND, being held virtually on December 9-11, 2020.

QurAlis co-founders and Harvard professors Kevin Eggan, Ph.D. and Clifford Woolf, M.D., Ph.D., members of the QurAlis Scientific and Clinical Advisory Boards, Brian Wainger, M.D., Ph.D. (Massachusetts General Hospital) and Merit Cudkowicz, M.D., M.Sc. (Massachusetts General Hospital), and other authors recently published in JAMA Neurology the results of a clinical study investigating the therapeutic potential of Kv7 agonism in ALS. The clinical data support QurAlis’ belief that a safe Kv7 opener could be an effective disease-modifying therapy for ALS patients with motor system hyperexcitability, an approach that QurAlis is pursing with its preclinical program investigating the regulation of the Kv7.2/7.3 ion channel.

The poster presentations will share, for the first time publicly, results from preclinical studies of QurAlis’ program investigating a novel Kv7.2/7.3 ion channel agonist as a potential treatment for motor neuron hyperexcitability and excitotoxicity, as well as its program targeting the TBK1 autophagy pathway.

“While KV7 agonists have shown great potential as a treatment for the 20-50% of ALS patients who present with hyperexcitability in their motor system, they can often cause undesired side effects such as dizziness and fatigue,” said Daniel Elbaum, Ph.D., Chief Scientific Officer of QurAlis. “The preclinical data we will be presenting show that the improved channel specificity of our novel Kv7.2/7.3 agonist could translate into an improved clinical safety profile with significant reduction in off-target adverse events. We look forward to sharing the full results of this preclinical study as well as discussing our autophagy program at the MNDA 31st International Symposium on ALS/MND.”

Details of the presentations are as follows:

Title: TBK1 Autophagy Pathway Disease Mechanisms in ALS

Authors: Erika Norabuena; Clinton Bourbonais; Kasper Roet, Ph.D.; Kevin Eggan, Ph.D.; Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.

Presenting Author: Erika Norabuena

Date/Time: December 9, 2020, 12:10pm-12:50pm ET

Poster/Abstract Number: TST-07

Link to abstract

Title: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients

Authors: Daniel Elbaum, Ph.D.; Sandy Hinckley, Ph.D.; Kasper Roet, Ph.D.

Presenting Author: Daniel Elbaum, Ph.D.

Date/Time: December 11, 2020, 7:05am-7:50am ET

Poster/Abstract Number: TST-20

Link to abstract

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the

Read more

Sidra’s Precision Medicine symposium ready for launch

Sidra Medicine has announced that it is all set to host the fifth edition of its flagship ‘Precision Medicine and Functional Genomics 2020’ (PMFG 2020). The symposium will be held online from December 5-7, providing resourceful ‘remote learning’ opportunities on account of the current pandemic restrictions, according to a press statement.
Attendees to PMFG 2020 will receive 14.25 hours credits for learning as approved by the Qatar Council of Healthcare Practitioners. The conference is being billed as one of the major scientific symposiums from the Middle East, dedicated to covering topics relevant to the current pandemic as well as the importance of precision medicine, the statement notes.
Registered attendees will be able to access various sessions – from live and on-demand programming – and hear from notable local and international speakers. PMFG 2020 will dedicate a special session on Covid-19, which sheds light on the testing and treatment strategies that are now in place, including examples of recent methods developed and enhanced in Qatar.
“Precision Medicine is a key focus area for our conference programme and indeed, for Qatar. Sidra Medicine has been working closely with our local partners to build capacity in this area in recent years, and considering growing global interest in making precision medicine a reality for patients, we are excited to share early success stories. PMFG 2020 will provide an engaging platform for speakers to present best practices, discuss case studies and explore future opportunities. It will also be a forum to present innovations using precision technologies, in tackling a variety of ongoing health challenges such as diabetes, cancer and Covid-19,” said Dr Khalid Fakhro, chief research officer, Sidra Medicine.
PMFG 2020 will feature global and local thought leaders, including Prof Sir Mark Caulfield – chief scientist, Genomics England, UK, who will talk about the ‘100,000 Genomes Project’ and health transformation. Other notable speakers include Prof Adolfo Garcia-Sastre, professor of Medicine and Microbiology, The Icahn School of Medicine, US, discussing the development of Covid-19 vaccines; Dr Stephen Hunger, chief, Division of Paediatric Oncology, and director, Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, US, discussing implementing new precision medicine and immunotherapy strategies in paediatric acute lymphoblastic leukaemia.
In addition, Dr Alan Shuldiner, vice-president, Regeneron Pharmaceuticals, Inc, New York, US, will discuss ‘The Regeneron Genetics Center at 1 million exomes: What have we learned’; in addition to Dr Virginia Pascual, Ronay Menschel Professor of Paediatrics, director, Drukier Institute for Children’s Health, Weill Cornell Medicine – New York, US, talking about ‘A Personalised Approach to Understand Systemic Lupus Erythematosus Heterogeneity’.
To register, preview the full agenda and see the speakers’ list, one has to visit https://www.sidra.org/pmfg.

Read more

Precision Medicine Market to Reach US$ 105.6 Billion by 2026, Globally |CAGR: 9.9%| UnivDatos Market Insights

NOIDA, India, Dec. 1, 2020 /PRNewswire/ — A comprehensive overview of the precision medicine market is recently added by UnivDatos Market Insights to its humongous database. The precision medicine market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, the precision medicine market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the precision medicine market at the global and regional levels. Global Precision Medicine Market is expected to grow at a CAGR of 9.9% from 2021-2026 to reach US$ 105.6 billion by 2026.

Market Overview

Precision medicine is known to be one of the most promising approaches for tackling the diseases that have thus far eluded effective treatments or cures. Several indications such as cancer, neurodegenerative diseases, and rare genetic conditions take an immense toll on individuals, families, and societies. Cancer is amongst the leading cause of mortality worldwide with an estimation of 9.6 million deaths in 2018. The most common cancers include lung (2.09 million cases), breast (2.09 million cases), colorectal (1.80 million cases), prostate (1.28 million cases), non-melanoma skin (1.04 million cases), stomach (1.03 million cases).

The rising demand for preventive care and advances in next-generation sequencing (NGS) technologies have resulted in an unprecedented proliferation and deluge of genomic sequence data, thereby driving the market growth of the precision medicine sector. In the last 15 years, the cost of mapping a human genome has fallen from US$ 100 million to below US$ 1,000, allowing the use of data from patient DNA to become a significant viable method to provide precise, actionable recommendations before symptoms occur. The growth of the industry is also fueled by scientific discovery, alignment of incentives, regulatory decisions, consumer interest and demand, and advances in technology. The growth of the market for precision medicine is also supported by the increasing patient adherence to treatment and rising prevalence of oncology indications.

Request Sample Copy of this Report @ https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Impact of COVID-19:

As the pandemic is spreading rapidly, clinicians treating COVID-19 are in desperate need of effective therapy, as the development of an effective vaccine remains a remote possibility. Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, there are more than 560 drug development programs in the pipeline with over 370 trials been reviewed by FDA. For instance, Boehringer Ingelheim initiated a Phase II study of BI 764198, a TRPC6 inhibitor to alleviate the damage to the lung and decrease the risk or severity of acute respiratory complications in patients hospitalized for COVID-19.

Ask for Price & Discounts @ https://univdatos.com/report/precision-medicine-market-current-analysis-and-forecast-2020-2026

Global Precision Medicine Market report is studied thoroughly with several aspects that would help stakeholders in making their decisions more curated.

By Technology, the market is primarily bifurcated into

  • Big Data Analytics
  • Bioinformatics
  • Gene Sequencing
  • Drug Discovery
  • Companion
Read more

Precision Medicine Market Poised to Grow at 11.5% By 20227

(MENAFN – GlobeNewsWire – Nasdaq) OTTAWA, Nov. 30, 2020 (GLOBE NEWSWIRE) — The global [To enable links contact MENAFN] precision medicine market value surpassed USD 59.16 billion in 2019 and expected to reach USD 141.33 billion by 2027.

Precision medicine is an emerging approach of treatment and prevention of disease that takes into account the individual variability in environment, genes, and lifestyle for each person. This approach allows researchers and doctors to predict more precisely that which treatment and prevention strategies for a particular disease will work on the specified groups of people.

Although the term “precision medicine” is currently new to the consumers, the concept has been a part of healthcare industry for many years. For instance, a person who requires a blood transfusion is not given blood from any random donor; instead, the blood type of donor is matched with the recipient prior transfusion to reduce the risk of complications. Although examples can be found in various areas of medicine, the role of precision medicine in everyday healthcare is relatively limited. Researchers are significantly working to expand this approach in many areas of healthcare and health in the coming years.

Get the Sample Pages of Report for More [email protected] [To enable links contact MENAFN]

Growth Factors

The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market. NGS technology provides the data related to the patient’s genetic makeup along with response of drugs on the patient, thereby raising the development of precision medicine for the treatment of diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is analyzed to play a significant role in the advancement of personalized therapeutics and diagnostics over the forecast period. Apart from the benefits offered by the precision medicine, they are highly expensive due to the application of high-end computational methods to examine individual genes projected to hinder the market growth.

Regional Snapshots

North America dominated the global precision medicine market with revenue share of nearly 40% in 2019 and expected to grow at an escalating pace during the forecast period. Technological advancement along with the presence of major players in the region contributes significantly towards the growth of the region. However, the Asia Pacific seeks to be the most opportunistic region in the precision medicine market owing to increasing cases of cancer and other diseases along with the health awareness among people.

View Full Report with Complete ToC @ [To enable links contact MENAFN]

Report Highlights

  • In 2019, North America captured more than 40% of the overall market value share in 2019 and projected to maintain its position in the coming years. Increasing prevalence of cancer along with the presence of key market players in the region expected to be the key factors contributing for the market growth in
Read more

Navigating the challenge of covering breakthrough therapies at MedCity INVEST Precision Medicine

provider venture capital, money

Our virtual MedCity INVEST Precision Medicine conference, December 9-11, will highlight aspects of precision medicine from the biopharma companies developing cell and gene therapies to diagnostics and the data sharing initiatives to support precision and personalized medicine.

One vexing part of any conversation on precision medicine and breakthrough therapies that have been developed and are continuing to work their way through clinical trials for cancer to rare disease is how to address the practical challenge of their high price tags. Although there are several models to cover the cost of these therapies such as Cigna’s Embarc Benefit Protection program, what happens when someone changes insurers when they change their job? What is fair for patients and what’s fair for companies? When do these conversations even start?

The panel, Reimbursement Models for Cell and Gene Therapies, will highlight some of the pros and cons of different models that are coming to market. Panelists include Laura Okpala, Director, Reimbursement Policy, Gilead Sciences, and Mark Trusheim, Strategic Director, NEWDIGS initiative at the MIT Center for Biomedical Innovation.

Here’s a preview of some of the sessions. Click here to see the agenda.

Interoperability Progress Report

How far have we progressed with sharing patient medical records? Patient data is key in unlocking riddles of medical science but interoperability is necessary to facilitate this. What companies are making an impact on a regional and national scale? What milestones are on the horizon? What obstacles continue to vex further advancement? How can we make medical records more accessible to patients?

Moderator: Elise Reuter, Senior Reporter, MedCity News
Speakers:
Kevin Chaney, Senior Program Manager, Office of the National Coordinator for Health IT
Ida Sim, M.D., Ph.D., Professor of Medicine, University of California, San Francisco
Niko Skievaski, Co-Founder and President, Redox

What It Takes To Build A Successful, Regional BioInnovation Hub
Philadelphia is one of many cities seeking to support the continued growth of cell and gene therapy and connected health industries. What do cities need to do to address education, training and other needs to support these sectors? This session will be held as part of Venture Cafe Philadelphia.

(sponsored by IBX)

Lisa Dalton, Chief People Officer, Spark Therapeutics
Audrey Greenberg, Executive Managing Director, The Discovery Labs
Tiffany Wilson, President & CEO, University City Science Center

Moderator: Michelle Histand, Director of Innovation, Independence Blue Cross

Register now and be part of the conversation at INVEST Precision Medicine.

Source Article

Read more

Precision Medicine Market Poised to Grow at 11.5% By 20227 – Press Release

OTTAWA, Nov. 30, 2020 (GLOBE NEWSWIRE) — The global precision medicine market value surpassed USD 59.16 billion in 2019 and expected to reach USD 141.33 billion by 2027.

Precision medicine is an emerging approach of treatment and prevention of disease that takes into account the individual variability in environment, genes, and lifestyle for each person. This approach allows researchers and doctors to predict more precisely that which treatment and prevention strategies for a particular disease will work on the specified groups of people.

Although the term “precision medicine” is currently new to the consumers, the concept has been a part of healthcare industry for many years. For instance, a person who requires a blood transfusion is not given blood from any random donor; instead, the blood type of donor is matched with the recipient prior transfusion to reduce the risk of complications. Although examples can be found in various areas of medicine, the role of precision medicine in everyday healthcare is relatively limited. Researchers are significantly working to expand this approach in many areas of healthcare and health in the coming years.

Get the Sample Pages of Report for More [email protected] https://www.precedenceresearch.com/sample/1085

Growth Factors

The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market. NGS technology provides the data related to the patient’s genetic makeup along with response of drugs on the patient, thereby raising the development of precision medicine for the treatment of diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is analyzed to play a significant role in the advancement of personalized therapeutics and diagnostics over the forecast period. Apart from the benefits offered by the precision medicine, they are highly expensive due to the application of high-end computational methods to examine individual genes projected to hinder the market growth.

Regional Snapshots

North America dominated the global precision medicine market with revenue share of nearly 40% in 2019 and expected to grow at an escalating pace during the forecast period. Technological advancement along with the presence of major players in the region contributes significantly towards the growth of the region. However, the Asia Pacific seeks to be the most opportunistic region in the precision medicine market owing to increasing cases of cancer and other diseases along with the health awareness among people.

View Full Report with Complete ToC@ https://www.precedenceresearch.com/precision-medicine-market

Report Highlights

  • In 2019, North America captured more than 40% of the overall market value share in 2019 and projected to maintain its position in the coming years. Increasing prevalence of cancer along with the presence of key market players in the region expected to be the key factors contributing for the market growth in the region. Furthermore, demand for precision medicine is mainly driven by favorable government initiatives and rising investment for
Read more

Dr Michael Korn Discusses Precision Medicine Progress in Various Cancers

There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, of University of California, San Francisco, and Caris Life Sciences.

There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco, and chief medical officer of Caris Life Sciences.

Transcript

Are there certain cancers where we’ve made more progress using precision medicine to make treatment decisions compared with other cancers?

Absolutely. I think what has turned out is there are certain clinical scenarios and diseases where there is lots of opportunity, lots of already existing data and those areas pave the road, I think for, you know, other disease settings that are following. And the best example is really lung cancer, where—first of all, it is one of the most frequent cancer types, affecting over 200,000 people in the United States every year—but we have learned a lot about the molecular features of this disease. And so, we’re not looking at lung cancer as one disease anymore. We’re looking at segments of the disease that have all the different types of treatments associated with them. And this has become standard now. The NCCN [National Comprehensive Cancer Network] guidelines recommend broad molecular testing for lung cancer, because of that complexity, and we know that this improves outcomes.

Other diseases are following. Like, I’ll give you an example: breast cancer, colorectal cancer are other big disease groups where this is following. So, we will see a kind of steady development until, in my opinion, it becomes standard to test every cancer being diagnosed right up front when the patient presents himself, at least in the advanced disease setting, to the oncologist.

Have we made more progress in solid tumors compared with liquid tumors?

These are kind of somewhat different worlds. There has been clearly tremendous progress on the side of solid tumor, kind of molecularly guided therapy. I think the hematologic world is following, but it depends very much on what aspect of hematology you’re looking at. So, certainly, in diseases like AML [acute myeloid leukemia], recurrent AML, we are still looking for a similar approach. Whereas in others, in lymphomas and so on, there might be already very established linkage between certain molecular findings and treatments.

Source Article

Read more

Precision medicine key to preventing disease developing later in life, Singapore News & Top Stories

SINGAPORE – An individual’s genes can determine the amount of risk he has of developing life-threatening conditions such as heart disease and in turn allows for early intervention.

This is central to the precision medicine programme here, said Professor Tan Chorh Chuan, the chief health scientist from the Ministry of Health and executive director at the Healthcare Transformation Office.

Prof Tan told a webinar on Wednesday (Nov 25) that the programme looks at the genome sequences of participants to help determine the cumulative risks of different diseases based on their genes.

This can be particularly useful for some complaints like premature heart disease, added Prof Tan, who was joined on the webinar panel by Prudential chief executive Dennis Tan and Health Promotion Board (HPB) CEO Zee Yoong Kang.

The event, which covered a broad range of health topics from diabetes and vaccines to strategies on how to stay healthy, is part of The Straits Times Reset 2021 webinar series. It was sponsored by Prudential and moderated by ST senior health correspondent Salma Khalik.

Prof Tan told the webinar that a condition known as familial hypercholesterolemia is caused when a person has a gene that results in high cholesterol levels at a much younger age. If that gene is present, the individual will have up to 20 times higher risk of heart disease – and at an earlier age.

“And then if we identify somebody, we can also test the family. So these preventive strategies will be part of precision health,” he added.

The HPB is working to make use of the clinical, behavioural and digital data as well as genetic data – with patient consent – to identify those at higher risk to allow for early intervention.

Prudential’s Mr Tan said Singaporeans need not be worried about being part of the programme or be concerned if they find out their genome sequences. Having “bad” genes will not make it harder for them to secure insurance policies, he assured.

Privacy is really important, Mr Tan said, adding that “we (Prudential) are very, very careful about such things”.

He said individuals ultimately have to take charge of their own health and should find out more. He said: “Preventive healthcare is all about them being in the driver’s seat, and going through the whole process of early detection, health screening and all.

“So I think as insurers, we will definitely support them.”

Ms Khalik noted that if a person learns that he is at a high risk of getting a certain disease, it will give him the time and opportunity to act before the ailment takes hold.

Source Article

Read more
  • Partner links